CoChat

IL-17R-EGFR axis links wound healing to tumorigenesis in Lrig1+ stem cells

Open access

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Abstract

Lrig1 marks a distinct population of stem cells restricted to the upper pilosebaceous unit in normal epidermis. Here we report that IL-17A–mediated activation of EGFR plays a critical role in the expansion and migration of Lrig1+ stem cells and their progenies in response to wounding, thereby promoting wound healing and skin tumorigenesis. Lrig1-specific deletion of the IL-17R adaptor Act1 or EGFR in mice impairs wound healing and reduces tumor formation. Mechanistically, IL-17R recruits EGFR for IL-17A–mediated signaling in Lrig1+ stem cells. While TRAF4, enriched in Lrig1+ stem cells, tethers IL-17RA and EGFR, Act1 recruits c-Src for IL-17A–induced EGFR transactivation and downstream activation of ERK5, which promotes the expansion and migration of Lrig1+ stem cells. This study demonstrates that IL-17A activates the IL-17R–EGFR axis in Lrig1+ stem cells linking wound healing to tumorigenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20171849

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. IL-17A–induced signaling in Lrig1+ cells promotes the migration and expansion of Lrig1 progenies. (A) Schematic diagram for data shown in B and C. TAM, tamoxifen. (B) Epidermal cells from tamoxifen-treated Lrig1CreERT2Act1f/– mice before IL-17A injection were sorted and analyzed with Western blot. (C) Paraffin sections of the ear skin were stained for GFP. (D) Schematic diagram for E–K. (E) Epidermal cells from tamoxifen-treated Lrig1CreERT2Act1f/– ROSA26-lsl-tdTomato mouse were sorted for tdTomato or GFP followed by Western blot. Epidermal cells from ear skin of indicated mice were analyzed by flow cytometry for GFP and tdTomato. (F) Distribution of Lrig1+ cells and their progenies (Lrig1-GL, Lrig1 genetically labeled) cells in untreated or IL-17A–treated mouse skin. SG, sebaceous gland; JZ, junction zone; Bu, bulge. (G) Staining of Lrig1+ cells (green) and Lrig1 progenies (Lrig1-GL; red) in ear (a) and dorsal (b) PSU. The asterisk indicates autofluorescence. (H) Sections of PBS and IL-17A–injected ears (a–d) or dorsal skin (e–h) from littermate mice of the indicated genotypes. (I) Quantification of indicated cells in PBS- and IL-17A–injected ears (a) or dorsal skin (b). 10 PSUs and adjacent IFE were analyzed. n = 5 mice. (J and K) IL-17A–injected ear (a) and dorsal skin (b) from littermate mice were stained for ΔNp63, keratin 14, Ki67, and tdTomato. All bar graphs show means ± SEM. ***, P < 0.001, t test. Bars, 50 µm. All data are representative of three independent experiments.
Figure 1. IL-17A–induced signaling in Lrig1+ cells promotes the migration and expansion of Lrig1 progenies. (A) Schematic diagram for data shown in B and C. TAM, tamoxifen. (B) Epidermal cells from tamoxifen-treated Lrig1CreERT2Act1f/– mice before IL-17A injection were sorted and analyzed with Western blot. (C) Paraffin sections of the ear skin were stained for GFP. (D) Schematic diagram for E–K. (E) Epidermal cells from tamoxifen-treated Lrig1CreERT2Act1f/– ROSA26-lsl-tdTomato mouse were sorted for tdTomato or GFP followed by Western blot. Epidermal cells from ear skin of indicated mice were analyzed by flow cytometry for GFP and tdTomato. (F) Distribution of Lrig1+ cells and their progenies (Lrig1-GL, Lrig1 genetically labeled) cells in untreated or IL-17A–treated mouse skin. SG, sebaceous gland; JZ, junction zone; Bu, bulge. (G) Staining of Lrig1+ cells (green) and Lrig1 progenies (Lrig1-GL; red) in ear (a) and dorsal (b) PSU. The asterisk indicates autofluorescence. (H) Sections of PBS and IL-17A–injected ears (a–d) or dorsal skin (e–h) from littermate mice of the indicated genotypes. (I) Quantification of indicated cells in PBS- and IL-17A–injected ears (a) or dorsal skin (b). 10 PSUs and adjacent IFE were analyzed. n = 5 mice. (J and K) IL-17A–injected ear (a) and dorsal skin (b) from littermate mice were stained for ΔNp63, keratin 14, Ki67, and tdTomato. All bar graphs show means ± SEM. ***, P < 0.001, t test. Bars, 50 µm. All data are representative of three independent experiments.CC BY-NC-SA · PubMed Central
Figure 2. IL-17A–induced signaling in Lrig1+ cells is required for the migration and expansion of Lrig1 progenies for wound healing. (A) Schematic diagram for data in B–D. TAM, tamoxifen. (B) Distribution of Lrig1 progenies in a healing wound. (C) Paraffin sections of reepithelializing wound from littermate mice were stained for tdTomato (red) and Ki67 (green) or ΔNp63 (green). Bar, 50 µm. (D) Quantifications of the indicated cells as a percentage of Krt14+ cells in the leading edge of the wound area. n = 10. Data are representative of three independent experiments shown in C and D. (E) Wound-closure kinetics in littermate mice of indicated genotypes. Graph shows the mean percentage of surface area that remained open as a percentage of original size. n = 10 wounds. (F) Schematic diagram in reference to G and H. The lengths of leading edges and the initial wound length were defined as indicated. (G) H&E staining (a) and staining for Krt14 (b) in reepithelializing wound. Bar, 500 µm. (H) Measurement of reepithelization ratio in wound area of Lrig1CreERT2Act1f/+ and littermate Lrig1CreERT2Act1f/– mice. n = 10 wounds. Data are representative of three independent experiments shown in E–H. All bar graphs in Fig. 2 show means ± SEM. ***, P < 0.001; **, P < 0.01; *, P < 0.05, t test.
Figure 2. IL-17A–induced signaling in Lrig1+ cells is required for the migration and expansion of Lrig1 progenies for wound healing. (A) Schematic diagram for data in B–D. TAM, tamoxifen. (B) Distribution of Lrig1 progenies in a healing wound. (C) Paraffin sections of reepithelializing wound from littermate mice were stained for tdTomato (red) and Ki67 (green) or ΔNp63 (green). Bar, 50 µm. (D) Quantifications of the indicated cells as a percentage of Krt14+ cells in the leading edge of the wound area. n = 10. Data are representative of three independent experiments shown in C and D. (E) Wound-closure kinetics in littermate mice of indicated genotypes. Graph shows the mean percentage of surface area that remained open as a percentage of original size. n = 10 wounds. (F) Schematic diagram in reference to G and H. The lengths of leading edges and the initial wound length were defined as indicated. (G) H&E staining (a) and staining for Krt14 (b) in reepithelializing wound. Bar, 500 µm. (H) Measurement of reepithelization ratio in wound area of Lrig1CreERT2Act1f/+ and littermate Lrig1CreERT2Act1f/– mice. n = 10 wounds. Data are representative of three independent experiments shown in E–H. All bar graphs in Fig. 2 show means ± SEM. ***, P < 0.001; **, P < 0.01; *, P < 0.05, t test.CC BY-NC-SA · PubMed Central
Figure 3. IL-17A–induced signaling in Lrig1+ cells drives Lrig1 progenies to participate in skin tumorigenesis. (A) Schematic diagram showing Cre-mediated ablation of Act1 and activation of KrasG12D in Lrig1 lineage cells. Time frame refers to B and C. 4-OHT, 4-hydroxytamoxifen. (B) Epidermal cells sorted based on GFP from LSL-Kras(G12D)Lrig1CreERT2Act1f/– mice were analyzed by Western blot. (C) Representative macroscopic photograph (day 20; A) of wound-induced tumors in indicated littermate mice and quantification of tumor incidence as a function of time. 10 wounds were evaluated per group. Data are representative of two independent experiments. Bar, 1 cm. (D) Schematic diagram for data shown in E–G. (E) Western blot analysis of epidermal cells sorted based on tdTomato or GFP from mice before wounding. (F) Schematic diagram showing the migration of Lrig1 progenies to the wounding site for tumorigenesis. SG, sebaceous gland; JZ, junction zone; Bu, bulge. (G) Wound-induced tumors were stained for indicated markers. Bar, 50 µm. Data were verified in three independent experiments shown in E–G. (H) Schematic diagram for data shown in I and J. (I and J) Photographs (I) and average tumor numbers (J) of the DMBA/TPA. n = 7. Data are representative of three independent experiments. Bar, 2 cm. (K) Schematic diagram for lineage tracing in DMBA/TPA model (a). DMBA/TPA-induced tumors from Lrig1CreERT2 ROSA26-lsl-tdTomato mice were stained for ΔNp63+ (green), Sox2+ (green), or CD34+ (green; b). Bars, 50 µm. (L) Quantification of the percentages of indicated cells in the Krt14+ tumor cells. 56 tumors were analyzed for tdTomato and Krt14; 14 tumors were analyzed for Krt14 in combination with ΔNp63, Sox2, or CD34. All bar graphs in Fig. 3 show means ± SEM. ***, P < 0.001; ns, not significant (P > 0.05), t test.
Figure 3. IL-17A–induced signaling in Lrig1+ cells drives Lrig1 progenies to participate in skin tumorigenesis. (A) Schematic diagram showing Cre-mediated ablation of Act1 and activation of KrasG12D in Lrig1 lineage cells. Time frame refers to B and C. 4-OHT, 4-hydroxytamoxifen. (B) Epidermal cells sorted based on GFP from LSL-Kras(G12D)Lrig1CreERT2Act1f/– mice were analyzed by Western blot. (C) Representative macroscopic photograph (day 20; A) of wound-induced tumors in indicated littermate mice and quantification of tumor incidence as a function of time. 10 wounds were evaluated per group. Data are representative of two independent experiments. Bar, 1 cm. (D) Schematic diagram for data shown in E–G. (E) Western blot analysis of epidermal cells sorted based on tdTomato or GFP from mice before wounding. (F) Schematic diagram showing the migration of Lrig1 progenies to the wounding site for tumorigenesis. SG, sebaceous gland; JZ, junction zone; Bu, bulge. (G) Wound-induced tumors were stained for indicated markers. Bar, 50 µm. Data were verified in three independent experiments shown in E–G. (H) Schematic diagram for data shown in I and J. (I and J) Photographs (I) and average tumor numbers (J) of the DMBA/TPA. n = 7. Data are representative of three independent experiments. Bar, 2 cm. (K) Schematic diagram for lineage tracing in DMBA/TPA model (a). DMBA/TPA-induced tumors from Lrig1CreERT2 ROSA26-lsl-tdTomato mice were stained for ΔNp63+ (green), Sox2+ (green), or CD34+ (green; b). Bars, 50 µm. (L) Quantification of the percentages of indicated cells in the Krt14+ tumor cells. 56 tumors were analyzed for tdTomato and Krt14; 14 tumors were analyzed for Krt14 in combination with ΔNp63, Sox2, or CD34. All bar graphs in Fig. 3 show means ± SEM. ***, P < 0.001; ns, not significant (P > 0.05), t test.CC BY-NC-SA · PubMed Central
Figure 4. IL-17A–induced EGFR activation in Lrig1+ stem cells is required for the migration and expansion of Lrig1 progenies. (A and B) Keratinocytes isolated from indicated mice were stimulated with IL-17A followed by Western blot analysis. (C) EGFRf/f primary keratinocytes infected with adenovirus expressing Cre-recombinase or GFP were then stimulated with IL-17A, followed by Western blot analysis. (D) EGFR-deficient HeLa cells reconstituted with WT EGFR, extracellular domain deletion (ΔExtra), and kinase dead mutant (D813N) were stimulated with IL-17A followed by Western blot analysis. Data shown in A–D are representative of three experiments. (E) Schematic diagram for data in F–H. TAM, tamoxifen. (F) Recombination efficiency in epidermal cells isolated from tamoxifen-injected Lrig1CreERT2EGFRf/f ROSA26-lsl-tdTomato mice. (G and H) Sections of PBS and IL-17A–injected ears (G, a–d; and H, a) and dorsal skin (G, e–h; and H, b) of the indicated littermate mice were analyzed for Lrig1 (green) and tdTomato (red; G). Representative PSU and adjacent IFE are shown. Quantification of indicated cells is presented in H. 10 PSUs and adjacent IFE were analyzed. n = 5 mice. Bar, 50 µm. Data are representative of three independent experiments in G (a–d) and two independent experiments in G (e–h). (I) Quantification of indicated cells for Fig. S3 H. 10 PSUs and adjacent IFE were analyzed. n = 5 mice. All bar graphs show means ± SEM. ***, P < 0.001; **, P < 0.01, t test. Bars, 50 µm. Data are representative of three independent experiments.
Figure 4. IL-17A–induced EGFR activation in Lrig1+ stem cells is required for the migration and expansion of Lrig1 progenies. (A and B) Keratinocytes isolated from indicated mice were stimulated with IL-17A followed by Western blot analysis. (C) EGFRf/f primary keratinocytes infected with adenovirus expressing Cre-recombinase or GFP were then stimulated with IL-17A, followed by Western blot analysis. (D) EGFR-deficient HeLa cells reconstituted with WT EGFR, extracellular domain deletion (ΔExtra), and kinase dead mutant (D813N) were stimulated with IL-17A followed by Western blot analysis. Data shown in A–D are representative of three experiments. (E) Schematic diagram for data in F–H. TAM, tamoxifen. (F) Recombination efficiency in epidermal cells isolated from tamoxifen-injected Lrig1CreERT2EGFRf/f ROSA26-lsl-tdTomato mice. (G and H) Sections of PBS and IL-17A–injected ears (G, a–d; and H, a) and dorsal skin (G, e–h; and H, b) of the indicated littermate mice were analyzed for Lrig1 (green) and tdTomato (red; G). Representative PSU and adjacent IFE are shown. Quantification of indicated cells is presented in H. 10 PSUs and adjacent IFE were analyzed. n = 5 mice. Bar, 50 µm. Data are representative of three independent experiments in G (a–d) and two independent experiments in G (e–h). (I) Quantification of indicated cells for Fig. S3 H. 10 PSUs and adjacent IFE were analyzed. n = 5 mice. All bar graphs show means ± SEM. ***, P < 0.001; **, P < 0.01, t test. Bars, 50 µm. Data are representative of three independent experiments.CC BY-NC-SA · PubMed Central
Figure 5. IL-17A–induced EGFR activation in Lrig1+ stem cells is required for IL-17A–dependent wound healing and tumorigenesis. (A) Schematic diagram for data shown in B–D. TAM, tamoxifen. (B) Paraffin sections of reepithelializing wound from littermate mice were stained for tdTomato (red) and Ki67 (green) or ΔNp63 (green). Bar, 50 µm. (C) Quantifications of the indicated cells as a percentage of Krt14+ cells in the leading edge of the wound area. n = 10 wounds. Data are representative of three independent experiments shown in B and C. (D) Wound-closure kinetics in age-matched littermate mice of indicated genotypes. Graph shows the mean percentage of surface area that remained open as a percentage of original size of the wound. n = 10 mice per group. (E) H&E staining of reepithelializing wound. Bar, 500 µm. (F) Measurement of reepithelization ratio (leading edge ratio). Data are representative of three independent experiments shown in D–F. (G) Schematic diagram for data shown in H and I. (H and I) Photographs (H) and average tumor numbers (I) of representative mice after DMBA/TPA treatment. n = 5 mice per group. Data are representative of three independent experiments. Bar, 2 cm. (J) Schematic diagram for data shown in K and L. (K) Western blot analysis of recombinant efficiency at KrasG12D and EGFR loci in epidermal cells sorted based on GFP from LSL-Kras(G12D) Lrig1CreERT2EGFRf/f mice. (L) Tumor incidence of wound-induced tumorigenesis in littermate mice of indicated genotype. n = 8 wounds per group. Data are representative of three independent experiments. All bar graphs show ± SEM. ***, P < 0.001; **, P < 0.01; *, P < 0.05, t test.
Figure 5. IL-17A–induced EGFR activation in Lrig1+ stem cells is required for IL-17A–dependent wound healing and tumorigenesis. (A) Schematic diagram for data shown in B–D. TAM, tamoxifen. (B) Paraffin sections of reepithelializing wound from littermate mice were stained for tdTomato (red) and Ki67 (green) or ΔNp63 (green). Bar, 50 µm. (C) Quantifications of the indicated cells as a percentage of Krt14+ cells in the leading edge of the wound area. n = 10 wounds. Data are representative of three independent experiments shown in B and C. (D) Wound-closure kinetics in age-matched littermate mice of indicated genotypes. Graph shows the mean percentage of surface area that remained open as a percentage of original size of the wound. n = 10 mice per group. (E) H&E staining of reepithelializing wound. Bar, 500 µm. (F) Measurement of reepithelization ratio (leading edge ratio). Data are representative of three independent experiments shown in D–F. (G) Schematic diagram for data shown in H and I. (H and I) Photographs (H) and average tumor numbers (I) of representative mice after DMBA/TPA treatment. n = 5 mice per group. Data are representative of three independent experiments. Bar, 2 cm. (J) Schematic diagram for data shown in K and L. (K) Western blot analysis of recombinant efficiency at KrasG12D and EGFR loci in epidermal cells sorted based on GFP from LSL-Kras(G12D) Lrig1CreERT2EGFRf/f mice. (L) Tumor incidence of wound-induced tumorigenesis in littermate mice of indicated genotype. n = 8 wounds per group. Data are representative of three independent experiments. All bar graphs show ± SEM. ***, P < 0.001; **, P < 0.01; *, P < 0.05, t test.CC BY-NC-SA · PubMed Central
Figure 6. TRAF4 is enriched in Lrig1+ stem cells. (A) Lrig1, EGFR, and TRAF4 expression in PSU and IFE in unchallenged skin. Paraffin sections of mouse ear were stained for EGFR, TRAF4, and Lrig1 (a–f). SG, sebaceous gland; JZ, junction zone; Bu, bulge. Quantification (g) of indicated cells over Lrig1+ cells in the PSU is presented. n = 15 hair follicles. Error bars represent ± SEM. Immunofluorescence staining for Lrig1 and TRAF4 was performed in dorsal skin (h). (B) Epidermal cells isolated from Lrig1CreERT2 mice sorted based on GFP (Lrig1) expression followed by Western blot analysis. Data are representative of three independent experiments. Normalized densitometric quantifications of p-IκBα are annotated above the blot. (C) Schematic diagram for data shown in D and E and Fig. S4 (F–I, a). Schematic summary of EGFR, Lrig1, TRAF4, and ΔNp63 expression pattern in IL-17A–injected skin (b). TAM, tamoxifen. (D and E) Ear and dorsal skin sections from indicated mice stained for Lrig1 (green) and TRAF4 (red; for ear [a–d] and dorsal skin [e–h]; D) or TRAF4 (green) and p63 (ΔNp63; red; for ear [a–d] and dorsal skin [e–h]; E). Representative PSU and adjacent IFE are shown. n = 5 mice per group. Data are representative of three independent experiments shown in D and E. Bars, 50 µm.
Figure 6. TRAF4 is enriched in Lrig1+ stem cells. (A) Lrig1, EGFR, and TRAF4 expression in PSU and IFE in unchallenged skin. Paraffin sections of mouse ear were stained for EGFR, TRAF4, and Lrig1 (a–f). SG, sebaceous gland; JZ, junction zone; Bu, bulge. Quantification (g) of indicated cells over Lrig1+ cells in the PSU is presented. n = 15 hair follicles. Error bars represent ± SEM. Immunofluorescence staining for Lrig1 and TRAF4 was performed in dorsal skin (h). (B) Epidermal cells isolated from Lrig1CreERT2 mice sorted based on GFP (Lrig1) expression followed by Western blot analysis. Data are representative of three independent experiments. Normalized densitometric quantifications of p-IκBα are annotated above the blot. (C) Schematic diagram for data shown in D and E and Fig. S4 (F–I, a). Schematic summary of EGFR, Lrig1, TRAF4, and ΔNp63 expression pattern in IL-17A–injected skin (b). TAM, tamoxifen. (D and E) Ear and dorsal skin sections from indicated mice stained for Lrig1 (green) and TRAF4 (red; for ear [a–d] and dorsal skin [e–h]; D) or TRAF4 (green) and p63 (ΔNp63; red; for ear [a–d] and dorsal skin [e–h]; E). Representative PSU and adjacent IFE are shown. n = 5 mice per group. Data are representative of three independent experiments shown in D and E. Bars, 50 µm.CC BY-NC-SA · PubMed Central
Figure 7. TRAF4 is required for IL-17A–induced IL-17RA–EGFR interaction. (A) TRAF4 WT and KO primary keratinocytes were treated with IL-17A followed by Western blot analysis. Normalized densitometric quantifications of p-IκBα are annotated above the blot. (B and C) Primary keratinocytes from WT and Act1 KO mice (B) or TRAF4 KO mice (C) treated with 100 ng/ml IL-17A were subjected to coimmunoprecipitation with anti-mouse–IL-17RA followed by Western blot analysis. WCL, whole cell lysate; IP, immunoprecipitation. (D) HeLa cells were transfected with IL-17RA and a vector or TRAF4. Transfected cells were treated with IL-17A and subjected to coimmunoprecipitation with anti-V5 (IL-17RA) followed by Western blot analysis. Data are representative of three independent experiments shown in A–D. (E) Stable HeLa cells that expressed TRAF4 in response to doxycycline were transfected with HA-tagged EGFR or the extracellular domain deletion mutant (ΔExtra), together with IL-17RA-Flag. PLAs were performed using anti-FLAG and anti-HA after 24 h of induction for TRAF4. Data are representative of at least three experiments. Graph represents percentage of PLA-positive cells from 10 fields. Bar graphs show ± SEM. ***, P < 0.001, t test. Scale bars, 50 µm.
Figure 7. TRAF4 is required for IL-17A–induced IL-17RA–EGFR interaction. (A) TRAF4 WT and KO primary keratinocytes were treated with IL-17A followed by Western blot analysis. Normalized densitometric quantifications of p-IκBα are annotated above the blot. (B and C) Primary keratinocytes from WT and Act1 KO mice (B) or TRAF4 KO mice (C) treated with 100 ng/ml IL-17A were subjected to coimmunoprecipitation with anti-mouse–IL-17RA followed by Western blot analysis. WCL, whole cell lysate; IP, immunoprecipitation. (D) HeLa cells were transfected with IL-17RA and a vector or TRAF4. Transfected cells were treated with IL-17A and subjected to coimmunoprecipitation with anti-V5 (IL-17RA) followed by Western blot analysis. Data are representative of three independent experiments shown in A–D. (E) Stable HeLa cells that expressed TRAF4 in response to doxycycline were transfected with HA-tagged EGFR or the extracellular domain deletion mutant (ΔExtra), together with IL-17RA-Flag. PLAs were performed using anti-FLAG and anti-HA after 24 h of induction for TRAF4. Data are representative of at least three experiments. Graph represents percentage of PLA-positive cells from 10 fields. Bar graphs show ± SEM. ***, P < 0.001, t test. Scale bars, 50 µm.CC BY-NC-SA · PubMed Central
Figure 8. TRAF4 tethers IL-17RA and EGFR through the TRAF domain. (A) A model for IL-17–induced IL-17R–EGFR complex formation. RA, IL-17RA; RC, IL-17RC; TK, tyrosine kinase domain; TM, transmembrane domain. (B) TRAF4-inducible HeLa clones were transfected with indicated plasmids, followed by induction of TRAF4 expression. Protein–protein interactions were detected by PLA (red dots). Graph represents mean percentage of PLA-positive cells from 10 fields. Error bars represent ± SEM. Data are representative of at least three experiments. ***, P < 0.001, t test. Bar, 50 µm. (C and D) IL-17RA-KO HeLa cells were transfected with indicated plasmids followed by coimmunoprecipitation. Deleted regions in mutant protein are shown in A. (E and F) EGFR-deficient HeLa cells were transfected with indicated plasmids and subjected to coimmunoprecipitation. Deleted regions in mutant protein are shown in A. (G) IL-17RA was cotransfected with EGFR (with/without pretreatment of gefitinib, EGFRi), kinase dead EGFR (D813N), or the extracellular domain deletion mutant (ΔExtra1-600) into EGFR-deficient HeLa cells with overexpression of TRAF4. Cell lysates were immunoprecipitated with anti-HA (EGFR), followed by Western blot analysis. (H) TRAF4-deficient HeLa cells were transfected with indicated TRAF4 plasmids (ΔRing, ΔZincFinger [ZF], and ΔTRAF) followed by coimmunoprecipitation. (I) TRAF4-deficient HeLa cells were transfected with the indicated plasmids followed by coimmunoprecipitation. (J) Structure–function analysis of TRAF4 for its ability to promote IL-17RA–EGFR interaction. All data are representative of three independent experiments shown in C–J. WCL, whole cell lysate; IP, immunoprecipitation. (K and L) Pull-down experiments with recombinant IL-17RA, TRAF4, and EGFR proteins. Data are representative of three independent pull-down experiments.
Figure 8. TRAF4 tethers IL-17RA and EGFR through the TRAF domain. (A) A model for IL-17–induced IL-17R–EGFR complex formation. RA, IL-17RA; RC, IL-17RC; TK, tyrosine kinase domain; TM, transmembrane domain. (B) TRAF4-inducible HeLa clones were transfected with indicated plasmids, followed by induction of TRAF4 expression. Protein–protein interactions were detected by PLA (red dots). Graph represents mean percentage of PLA-positive cells from 10 fields. Error bars represent ± SEM. Data are representative of at least three experiments. ***, P < 0.001, t test. Bar, 50 µm. (C and D) IL-17RA-KO HeLa cells were transfected with indicated plasmids followed by coimmunoprecipitation. Deleted regions in mutant protein are shown in A. (E and F) EGFR-deficient HeLa cells were transfected with indicated plasmids and subjected to coimmunoprecipitation. Deleted regions in mutant protein are shown in A. (G) IL-17RA was cotransfected with EGFR (with/without pretreatment of gefitinib, EGFRi), kinase dead EGFR (D813N), or the extracellular domain deletion mutant (ΔExtra1-600) into EGFR-deficient HeLa cells with overexpression of TRAF4. Cell lysates were immunoprecipitated with anti-HA (EGFR), followed by Western blot analysis. (H) TRAF4-deficient HeLa cells were transfected with indicated TRAF4 plasmids (ΔRing, ΔZincFinger [ZF], and ΔTRAF) followed by coimmunoprecipitation. (I) TRAF4-deficient HeLa cells were transfected with the indicated plasmids followed by coimmunoprecipitation. (J) Structure–function analysis of TRAF4 for its ability to promote IL-17RA–EGFR interaction. All data are representative of three independent experiments shown in C–J. WCL, whole cell lysate; IP, immunoprecipitation. (K and L) Pull-down experiments with recombinant IL-17RA, TRAF4, and EGFR proteins. Data are representative of three independent pull-down experiments.CC BY-NC-SA · PubMed Central
Figure 9. Tyrosine kinase c-Src is required for IL-17–induced EGFR transactivation. (A) Primary keratinocytes with and without pretreatment of Src inhibitor (PP2, 8 µM) were stimulated with IL-17A followed by Western blot analysis. (B) Putative SH3 binding motif in Act1. (C) Act1 KO keratinocytes were infected with retrovirus expressing Act1 WT, empty vector, or Act1 SH3 binding mutant (PRPP-ARAA, Act1SH3Bm) and treated with IL-17A. Treated cells were subjected to coimmunoprecipitation followed by Western blot. (D) Act1 KO keratinocytes were restored with WT Act1 and mutants as in C. Cells were then treated with IL-17A and subjected to coimmunoprecipitation. (E) Primary keratinocytes pretreated with 10 µM gefitinib were stimulated with IL-17A. Cell lysates were then immunoprecipitated with anti–TRAF4. (F) Primary keratinocytes with pretreatment of gefitinib were stimulated with IL-17A followed by coimmunoprecipitation Western blot. Data are representative of three independent experiments shown in A–F. WCL, whole cell lysate; IP, immunoprecipitation. (G) Lrig1CreERT2 mice were intradermally injected with PBS and IL-17A combined with gefitinib or pp2. Ear skin sections from these age-matched littermate mice were stained for Lrig1 (green) and ΔNp63 (red; a) or TRAF4 (green) and ΔNp63 (red; b). Bars, 50 µm. The asterisk indicates nonspecific staining. (H and I) Quantification of indicated cells for the data presented in Fig. 6 G. 10 PSUs and adjacent IFE were analyzed each group. Bar graphs show means ± SEM. ***, P < 0.001, t test. Data are representative of three independent experiments.
Figure 9. Tyrosine kinase c-Src is required for IL-17–induced EGFR transactivation. (A) Primary keratinocytes with and without pretreatment of Src inhibitor (PP2, 8 µM) were stimulated with IL-17A followed by Western blot analysis. (B) Putative SH3 binding motif in Act1. (C) Act1 KO keratinocytes were infected with retrovirus expressing Act1 WT, empty vector, or Act1 SH3 binding mutant (PRPP-ARAA, Act1SH3Bm) and treated with IL-17A. Treated cells were subjected to coimmunoprecipitation followed by Western blot. (D) Act1 KO keratinocytes were restored with WT Act1 and mutants as in C. Cells were then treated with IL-17A and subjected to coimmunoprecipitation. (E) Primary keratinocytes pretreated with 10 µM gefitinib were stimulated with IL-17A. Cell lysates were then immunoprecipitated with anti–TRAF4. (F) Primary keratinocytes with pretreatment of gefitinib were stimulated with IL-17A followed by coimmunoprecipitation Western blot. Data are representative of three independent experiments shown in A–F. WCL, whole cell lysate; IP, immunoprecipitation. (G) Lrig1CreERT2 mice were intradermally injected with PBS and IL-17A combined with gefitinib or pp2. Ear skin sections from these age-matched littermate mice were stained for Lrig1 (green) and ΔNp63 (red; a) or TRAF4 (green) and ΔNp63 (red; b). Bars, 50 µm. The asterisk indicates nonspecific staining. (H and I) Quantification of indicated cells for the data presented in Fig. 6 G. 10 PSUs and adjacent IFE were analyzed each group. Bar graphs show means ± SEM. ***, P < 0.001, t test. Data are representative of three independent experiments.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

Items 101–113 of 113

Metadata

Authors
Chen, X., Cai, G., Liu, C., Zhao, J., Gu, C., Wu, L., Hamilton, T. A., Zhang, C.-J., Ko, J., Zhu, L., Qin, J., Vidimos, A., Koyfman, S., Gastman, B. R., Jensen, K. B., & Li, X.
Affiliations
  • Cleveland Clinic (US)
  • University of Copenhagen (DK)
Corresponding author
Li, Xiaoxia
Venue
Journal of Experimental Medicine
Published
2018-12-21
Volume
216
Issue
1
Pages
195-214
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2905823481
Cited by
106
References
66
Citations by year
2026: 4 · 2025: 6 · 2024: 15 · 2023: 19 · 2022: 17 · 2021: 20 · 2020: 17 · 2019: 8
FWCI
4.22
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-sa)
Funders
  • National Institutes of Health (5P01CA062220, 5P01 HL103453)
  • National Institutes of Health Shared Instrumentation Grant (S10-OD019972)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
IL-17A, IL-17 receptor, EGFR, Lrig1, epidermal stem cells, wound healing, skin carcinogenesis, Act1, TRAF4, Src kinase, ERK5, EGFR transactivation, stem cell migration, pilosebaceous unit
MeSH terms
CSK Tyrosine-Protein Kinase, Animals, Epidermis, HeLa Cells, Humans, Membrane Glycoproteins, Nerve Tissue Proteins, Stem Cells, Wound Healing, Signal Transduction, Mice, Knockout, src-Family Kinases, Adaptor Proteins, Signal Transducing, Mice, Receptors, Interleukin-17, Carcinogenesis, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.